Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

Core Viewpoint - Citius Pharmaceuticals Inc. has announced a definitive agreement to purchase 1,739,131 shares of its common stock at a price of $1.15 per share, with expected gross proceeds of approximately $2 million to support the commercial launch of LYMPHIR™ and general corporate purposes [1][2]. Group 1 - The offering is being facilitated by H.C. Wainwright & Co. as the exclusive placement agent [2]. - The closing of the offering is anticipated to occur on or about April 2, 2025, pending customary closing conditions [1]. - The securities are being offered under a "shelf" registration statement filed with the SEC, which became effective on March 1, 2024 [3]. Group 2 - Citius Pharmaceuticals is focused on developing first-in-class critical care products, with LYMPHIR approved by the FDA in August 2024 for treating cutaneous T-cell lymphoma [5]. - The company's late-stage pipeline includes Mino-Lok®, an antibiotic lock solution, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief, with both products having completed pivotal trials in 2023 [5]. - Citius Pharma owns 92% of Citius Oncology, Inc., indicating a strong position in the oncology sector [5].